PD-1 inhibitors pembrolizumab and nivolumab as well as the PD-L1 inhibitors atezolizumab, avelumab, and durvalumab have all been approved in succession by the Food and Drug Administration (FDA) for treating patients with metastatic NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.